Jun 24, 2022

---

Elizabeth Brem, MD, on Frontline Management of CLL

In the last few years, frontline management of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) has undergone a profound paradigm shift. First-line treatment with novel targeted therapies has become preferable to the use of chemoimmunotherapy regimens such as fludarabine, cyclophosphamide, and rituximab (FCR) -- the latter being largely reserved for patients younger than 65 with no comorbidities, and no 17p deletion or other TP53 mutations.

Dec 21, 2021

---

Virus-based sensor detects bladder cancer markers in urine

Researchers have made a virus-based biosensor that detects markers of bladder cancer in urine. Their goal is to make a dipstick that can quickly detect bladder cancer as part of routine urinalysis.

Oct 21, 2021

---

NPR Academic Minute - "Follow-Up Care for Young Adult Cancer Survivors"

On University of California, Irvine Week: Lifelong follow up care is critical for young cancer survivors. Joel Milam, professor of epidemiology, examines why. Joel Milam, PhD, is a professor of epidemiology and biostatistics at the University of California, Irvine's Program in Public Health. He also has an adjunct appointment at the UCI School of Medicine's Department of Hematology/Oncology. Dr. Milam's research focuses on young adult cancer survivorship, positive psychology, and HIV prevention/control. Dr. Milam's interest in cancer research led him to become the Co-Leader of the Cancer Control Program at the Chao Family Comprehensive Cancer Center, where he facilitates research to identify and reduce cancer risk, and improve quality of life throughout the cancer care trajectory. Aside from teaching at UCI, Dr. Milam is a Co-Founder & Co-Director of the Center for Young Adult Cancer Survivorship Research. The Center is an interdisciplinary collaborative, including affiliate faculty, trainees, and patient advocates at UCI and USC.

Oct 20, 2021

---

NPR Academic Minute - "The Central Role of Social Support in the Health of Chinese and Korean American Immigrants"

Immigrants can thrive with a strong support network. Brittany Morey, assistant professor of health, society and behavior, explores why. Brittany N. Morey, PhD, MPH, is an Assistant Professor of Public Health at University of California, Irvine.

Oct 13, 2021

---

Survivor beats breast cancer, not once but twice

LeeAnn Brill first came to UCI Health in 2015 when she was diagnosed with a rare and aggressive cancer in her right breast. Determined to find the best care and most advanced treatments possible, the registered pharmacist used her considerable research skills.

Oct 06, 2021

---

UCI-led study finds psychological therapy reduces biobehavioral impact of testicular cancer

Psychological therapy reduces the adverse biobehavioral effects of testicular cancer in young adult survivors, according to a pilot study led by the University of California, Irvine. Biobehavior is the interaction of biological processes and behavior. Researchers’ findings, published in the American Journal of Men’s Health, show that Goal-focused Emotion-regulation Therapy, developed specifically to enhance the quality of life for these patients, reduced the stress hormone cortisol and the proinflammatory cell protein cytokine IL-1ra that triggers fatigue, pain and other side effects.

Sep 27, 2021

---

John Wayne Cancer Foundation gift establishes new surgical oncology fellowship training program at UCI

A gift from the John Wayne Cancer Foundation will establish the John Wayne Cancer Foundation Endowed Chair in Surgical Oncology and also fund the UCI John Wayne Cancer Foundation Endowed Fellowship in Surgical Oncology at the UCI School of Medicine.

Sep 01, 2021

---

A Marine Bacteria Species Shows Promise for Curing an Aggressive Brain Cancer

Glioblastoma cells are especially adept at dividing quickly; an untreated tumor doubles in size in just two weeks. But that speed comes at a cost, and Bota hoped to take advantage of the cells’ vulnerability. The problem was that none of the available proteasome inhibitors could cross the blood-brain barrier to target glioblastomas where they bloom. Bota, who by then had started her own lab at the University of California, Irvine, found herself thinking about the Nereus presentation.